| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis
|
Zhou, Susu
|
|
|
19 |
4 |
p. 547-564
|
article
|
| 2 |
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
|
Persano, Mara
|
|
|
19 |
4 |
p. 645-659
|
article
|
| 3 |
Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis
|
Van Nguyen, Tai
|
|
|
19 |
4 |
p. 533-545
|
article
|
| 4 |
A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
|
Gupta, Shilpa
|
|
|
19 |
4 |
p. 483-494
|
article
|
| 5 |
Comment on: “Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer”
|
Han, Wei
|
|
|
19 |
4 |
p. 661-662
|
article
|
| 6 |
Correction to: Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer
|
Li, Yuan
|
|
|
19 |
4 |
p. 663
|
article
|
| 7 |
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
|
Uchimoto, Taizo
|
|
|
19 |
4 |
p. 635-644
|
article
|
| 8 |
Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer
|
Li, Yuan
|
|
|
19 |
4 |
p. 601-610
|
article
|
| 9 |
Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib
|
Papazyan, Thomas
|
|
|
19 |
4 |
p. 611-621
|
article
|
| 10 |
Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review
|
Fowler, Nathan Hale
|
|
|
19 |
4 |
p. 495-510
|
article
|
| 11 |
Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study
|
Kagawa, Yoshinori
|
|
|
19 |
4 |
p. 575-585
|
article
|
| 12 |
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
|
Fiala, Ondřej
|
|
|
19 |
4 |
p. 587-599
|
article
|
| 13 |
Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group
|
Salgado Fernández, Mercedes
|
|
|
19 |
4 |
p. 565-573
|
article
|
| 14 |
Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma
|
Yoshino, Maki
|
|
|
19 |
4 |
p. 623-633
|
article
|
| 15 |
Targeted Alpha Therapy for Glioblastoma: Review on In Vitro, In Vivo and Clinical Trials
|
Sabri, Maram El
|
|
|
19 |
4 |
p. 511-531
|
article
|
Journal description